Dates: July 26-30, 2025
Location: San Diego Convention Center, California, USA
Organizer: Alzheimer's Association
Website: aaic.alz.org
The Alzheimer's Association International Conference (AAIC) 2025 was held in San Diego, California. This annual event is the world's largest gathering of dementia researchers, bringing together over 5,000 scientists, clinicians, and care professionals to showcase advances in Alzheimer's disease and related dementias.
The 2025 conference featured significant data on anti-amyloid monoclonal antibodies, building on the approvals of lecanemab (Leqembi) and donanemab (Kisunla). Key topics included:
- Real-world effectiveness data from clinic-based populations
- ARIA (Amyloid-Related Imaging Abnormalities) management protocols
- Combination therapy approaches targeting multiple pathological proteins
- Early intervention benefits in preclinical and prodromal stages
Tau pathology was a major focus, with multiple tau-targeted agents in development:
- Tau PET imaging correlations with clinical outcomes
- Anti-tau antibodies in Phase 2 and 3 trials
- Small molecule tau aggregation inhibitors
- Tau spreading mechanisms and therapeutic interception points
Blood biomarkers emerged as a transformative topic:
- p-tau217 clinical implementation and reimbursement
- p-tau181 utility in primary care settings
- Neurofilament light chain (NfL) for disease progression
- Combination biomarker panels for enhanced diagnostic accuracy
The role of neuroinflammation in AD pathogenesis received substantial attention:
- Microglial activation phenotypes and therapeutic targeting
- Complement system involvement in synaptic loss
- Inflammatory cytokines as biomarkers and therapeutic targets
- TREM2 variants and microglia modulation strategies
- "The Future of Alzheimer's Prevention" — Overview of prevention trials in at-risk populations
- "Biomarker-Driven Diagnosis and Treatment" — Integrating biomarkers into clinical practice
- "Diversity in Alzheimer's Research" — Addressing health disparities in clinical trials
- Results from the CLARITY-AD open-label extension study
- Donanemab TRAILBLAZER-ALZ 2 long-term follow-up data
- Lecanemab CLARITY-AD 3-year outcomes
- Novel anti-Aβ protofibril antibodies entering clinical trials
- Population-based studies on modifiable risk factors
- Lifestyle interventions and cognitive reserve
- Early-life risk factor modification
¶ Care and Support
- Dementia care models in diverse communities
- Technology-assisted monitoring and support
- Caregiver burden interventions
Located in downtown San Diego, the convention center offers:
- State-of-the-art presentation facilities
- Proximity to hotels and restaurants
- Waterfront views of San Diego Bay
San Diego is home to a vibrant research community including: